Table 2 Synergistic interaction between JAKi and gefitinib on cell viability in a variety of human ovarian cancer cell lines
Cells | JAKi: Gefitinib | Combination index (CI) | Fold reduction (gefitinib) | ||||
|---|---|---|---|---|---|---|---|
ED50 | ED75 | ED90 | IC50 | IC75 | IC90 | ||
SKOV3 | 1:1 | 0.32 | 0.11 | 0.048 | 16.13 | 117.14 | 1764.86 |
MDAH2774 | 1:2 | 0.36 | 0.41 | 0.59 | 5.33 | 10.92 | 22.38 |
OVCAR 3 | 1:4 | 0.29 | 0.29 | 0.37 | 33.11 | 145.78 | 645.24 |
OVCAR 8 | 1:2 | 0.69 | 0.57 | 0.47 | 4.15 | 6.52 | 10.23 |